These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27389279)

  • 1. Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
    Garcia PV; Seiva FR; Carniato AP; de Mello Júnior W; Duran N; Macedo AM; de Oliveira AG; Romih R; Nunes Ida S; Nunes Oda S; Fávaro WJ
    BMC Cancer; 2016 Jul; 16():422. PubMed ID: 27389279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model.
    Fávaro WJ; Socca EAR; Böckelmann PK; Reis IB; Garcia PV; Durán N
    Med Oncol; 2022 Jan; 39(2):24. PubMed ID: 34982270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.
    Garcia PV; Apolinário LM; Böckelmann PK; da Silva Nunes I; Duran N; Fávaro WJ
    Int J Clin Exp Pathol; 2015; 8(5):4427-43. PubMed ID: 26191134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with p - mapa and systemic administration of cisplatin and doxorubicin.
    Dias QC; Nunes ID; Garcia PV; Favaro WJ
    Int Braz J Urol; 2016; 42(5):942-954. PubMed ID: 24893914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
    de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
    J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OncoTherad® (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway.
    Reis IB; Tibo LHS; Socca EAR; de Souza BR; Durán N; Fávaro WJ
    Tissue Cell; 2022 Jun; 76():101762. PubMed ID: 35245856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guérin Downregulation of Nonmuscle-invasive Bladder Cancer.
    Camargo JA; Passos GR; Ferrari KL; Billis A; Saad MJA; Reis LO
    Clin Genitourin Cancer; 2018 Jun; 16(3):e587-e593. PubMed ID: 29174504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OncoTherad
    Alonso JCC; de Souza BR; Reis IB; de Arruda Camargo GC; de Oliveira G; de Barros Frazão Salmazo MI; Gonçalves JM; de Castro Roston JR; Caria PHF; da Silva Santos A; de Freitas LLL; Billis A; Durán N; Fávaro WJ
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer.
    Dias LP; Luzo ÂCM; Volpe BB; Durán M; Galdames SEM; Ferreira LAB; Durán N; Fávaro WJ
    Tissue Cell; 2018 Jun; 52():17-27. PubMed ID: 29857824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
    Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
    Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study.
    Lupi LA; Delella FK; Cucielo MS; Romagnoli GG; Kaneno R; Nunes IDS; Domeniconi RF; Martinez M; Martinez FE; Fávaro WJ; Chuffa LGA
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31861351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
    Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
    Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
    Huang Z; Liu H; Wang Y; Zhang C; Xu T
    Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
    Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
    Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad® immunotherapy associated with platelet-rich plasma.
    Ribeiro de Souza B; Brum Reis I; Cardoso de Arruda Camargo G; Oliveira G; Cristina Dias Q; Durán N; José Fávaro W
    Int Immunopharmacol; 2023 Oct; 123():110723. PubMed ID: 37531827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.
    Passos GR; Camargo JA; Ferrari KL; Saad MJA; de Mattos AC; Reis LO
    Med Oncol; 2017 Dec; 35(1):3. PubMed ID: 29209984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.